Repligen (FRA:RGN) Ending Cash Position : €644.9 Mil (As of Mar. 2025)

View and export this data going back to . Start your Free Trial

What is Repligen Ending Cash Position?

Repligen's Ending Cash Position for the quarter that ended in Mar. 2025 was €644.9 Mil.

Repligen's quarterly Ending Cash Position increased from Sep. 2024 (€706.4 Mil) to Dec. 2024 (€723.3 Mil) but then declined from Dec. 2024 (€723.3 Mil) to Mar. 2025 (€644.9 Mil).

Repligen's annual Ending Cash Position increased from Dec. 2022 (€494.1 Mil) to Dec. 2023 (€689.0 Mil) and increased from Dec. 2023 (€689.0 Mil) to Dec. 2024 (€723.3 Mil).

Repligen Ending Cash Position Historical Data

The historical data trend for Repligen's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Repligen Ending Cash Position Chart

Repligen Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Ending Cash Position

Get a 7-Day Free Trial

589.61

534.38

494.14

688.96

723.27

Repligen Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Ending Cash Position	Get a 7-Day Free Trial															718.17	751.70	706.35	723.27	644.94

Repligen Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Repligen's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	717.514	+	5.76
	=	723.3

Repligen's Ending Cash Position for the quarter that ended in Mar. 2025 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	700.554	+	-55.617
	=	644.9

Repligen Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Repligen's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Repligen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Repligen Corp (FRA:RGN) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

RGEN:USA RGN:Germany

Address

41 Seyon Street, Building 1, Suite 100, Waltham, MA, USA, 02453

Website

https://www.repligen.com

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

Repligen Headlines

No Headlines